{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=13",
    "query": {
      "condition": "Advanced Nonsmall Cell Lung Cancer",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 1770,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Nonsmall+Cell+Lung+Cancer&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T22:26:40.587Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00684801",
      "title": "Disease Management Program or Usual Care in Patients With Stage III or Stage IV Lung Cancer, Pancreatic Cancer, Ovarian Cancer, or Colorectal Cancer, and Their Caregivers",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Colorectal Cancer",
        "Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 605,
      "start_date": "2007-08",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-09",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684801"
    },
    {
      "nct_id": "NCT04486833",
      "title": "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "quaratusugene ozeplasmid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Platinum-Based Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genprex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 158,
      "start_date": "2021-09-03",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04486833"
    },
    {
      "nct_id": "NCT03170206",
      "title": "Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-05-31",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-12",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170206"
    },
    {
      "nct_id": "NCT03707938",
      "title": "Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Lung Carcinoma",
        "ALK Gene Rearrangement",
        "Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IVA Lung Cancer AJCC v8",
        "Stage IVB Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Brigatinib",
          "type": "DRUG"
        },
        {
          "name": "Local Consolidation Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2018-12-18",
      "completion_date": "2028-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707938"
    },
    {
      "nct_id": "NCT05565378",
      "title": "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer, Non-Small Cell"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Dostarlimab",
          "type": "DRUG"
        },
        {
          "name": "Belrestotug",
          "type": "DRUG"
        },
        {
          "name": "Nelistotug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 351,
      "start_date": "2022-10-14",
      "completion_date": "2027-12-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-09",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 4,
      "location_summary": "Plantation, Florida • Albuquerque, New Mexico • Chattanooga, Tennessee + 1 more",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Chattanooga",
          "state": "Tennessee"
        },
        {
          "city": "Morgantown",
          "state": "West Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05565378"
    },
    {
      "nct_id": "NCT00080340",
      "title": "Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non Small Cell Lung Carcinoma"
      ],
      "interventions": [
        {
          "name": "TLK286 (Telcyta) HCl for Injection",
          "type": "DRUG"
        },
        {
          "name": "gefitinib (Iressa)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Telik",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 520,
      "start_date": null,
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 270,
      "location_summary": "Birmingham, Alabama • Glendale, Arizona • Benton, Arkansas + 174 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080340"
    },
    {
      "nct_id": "NCT00308750",
      "title": "First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "enzastaurin",
          "type": "DRUG"
        },
        {
          "name": "pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 218,
      "start_date": "2006-03",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2021-05-13",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 4,
      "location_summary": "Burlington, North Carolina • Chapel Hill, North Carolina • Columbia, South Carolina + 1 more",
      "locations": [
        {
          "city": "Burlington",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbia",
          "state": "South Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00308750"
    },
    {
      "nct_id": "NCT05107674",
      "title": "A Study of NX-1607 in Adults With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer, Epithelial",
        "Gastric Cancer",
        "GastroEsophageal Junction (GEJ) Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Metastatic or Unresectable Melanoma",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "Malignant Pleural Mesothelioma (MPM)",
        "Triple Negative Breast Cancer (TNBC)",
        "Metastatic Urothelial Carcinoma",
        "Cervical Cancer",
        "Diffuse Large B Cell Lymphoma (DLBCL)",
        "Richter Transformation",
        "Microsatellite Stable Colorectal Carcinoma"
      ],
      "interventions": [
        {
          "name": "NX-1607",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nurix Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 345,
      "start_date": "2021-09-29",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-09-09",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107674"
    },
    {
      "nct_id": "NCT03191149",
      "title": "Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lung Non-Small Cell Carcinoma",
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IIIB Lung Non-Small Cell Cancer AJCC v7",
        "Stage IV Lung Non-Small Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography with Contrast",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2018-04-25",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 347,
      "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03191149"
    },
    {
      "nct_id": "NCT01248247",
      "title": "BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "AZD6244",
          "type": "DRUG"
        },
        {
          "name": "MK-2206",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 334,
      "start_date": "2011-06-02",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-11-18T22:26:40.587Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01248247"
    }
  ]
}